Researchers warn that the drug-resistant fungus Candida auris continues its rapid spread across U.S. healthcare facilities, with over 7,000 cases reported in 2025 alone across at least 27 states. This emerging pathogen, often resistant to multiple antifungal drugs, poses a severe threat primarily to hospitalized patients with weakened immune systems or invasive medical devices.
Hackensack Meridian Center for Discovery and Innovation scientists highlighted in a recent review how C. auris evades human immune responses and adapts to survive on skin and surfaces. The fungus switches growth forms to spread more effectively and persists in hospital environments despite standard cleaning protocols.
First identified in 2009, C. auris arrived in the U.S. in 2016 and has since caused outbreaks that forced temporary closures of intensive care units. Centers for Disease Control and Prevention data show cases tripling in resistant strains to echinocandins, the primary treatment option, raising alarms about limited therapeutic choices.
High-risk groups include those on ventilators, with central lines, or in long-term care. Infections manifest as bloodstream, wound, or ear issues, often proving difficult to diagnose due to misidentification by common lab tests. Mortality rates reach up to 60% in severe cases, though many patients have underlying conditions.
Healthcare facilities combat spread through enhanced screening, isolation, and rigorous disinfection with EPA-registered agents effective against C. auris. Hand hygiene and equipment cleaning remain critical, as the fungus transfers via contaminated surfaces or hands.
Public health experts stress improved surveillance, especially in lower-resource settings, to track and contain outbreaks. While healthy individuals face low risk, the fungus’s persistence underscores the broader antimicrobial resistance crisis affecting global health security.
Ongoing research targets vulnerabilities in C. auris for new treatments or vaccines. Current efforts focus on better diagnostics and infection control to curb transmission before resistance renders existing drugs ineffective.
America faces this challenge amid rising resistant infections overall. Vigilance in medical settings protects vulnerable populations from preventable harm caused by this adaptable pathogen.